Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$2.19.

  • Avalo Therapeutics' EPS (Basic) fell 32346.94% to -$2.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.31, marking a year-over-year increase of 2797.62%. This contributed to the annual value of -$7.94 for FY2024, which is 9300.93% up from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' EPS (Basic) is -$2.19, which was down 32346.94% from -$1.92 recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' EPS (Basic) ranged from a high of $117.47 in Q4 2023 and a low of -$1059.6 during Q4 2022
  • Moreover, its 5-year median value for EPS (Basic) was -$2.09 (2021), whereas its average is -$77.58.
  • The largest annual percentage gain for Avalo Therapeutics' EPS (Basic) in the last 5 years was 11626.79% (2022), contrasted with its biggest fall of 5480207.25% (2022).
  • Quarter analysis of 5 years shows Avalo Therapeutics' EPS (Basic) stood at -$1.93 in 2021, then tumbled by 54802.07% to -$1059.6 in 2022, then skyrocketed by 111.09% to $117.47 in 2023, then crashed by 106.77% to -$7.95 in 2024, then skyrocketed by 72.45% to -$2.19 in 2025.
  • Its EPS (Basic) was -$2.19 in Q3 2025, compared to -$1.92 in Q2 2025 and -$1.25 in Q1 2025.